Reappraising 21 years of the WHI study: Putting the findings in context for clinical practice.

Stute, Petra; Marsden, Jo; Salih, Noor; Cagnacci, Angelo (2023). Reappraising 21 years of the WHI study: Putting the findings in context for clinical practice. Maturitas, 174, pp. 8-13. Elsevier 10.1016/j.maturitas.2023.04.271

Preview

Text 1-s2.0-S0378512223003584-main.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (503kB) | Preview

Menopausal hormone treatment (MHT) is recommended for the management of menopause symptoms. The Women's Health Initiative (WHI) placebo-controlled randomised study examined the effects of continuous combined or estrogen-only MHT on the risk of non-communicable diseases (NCDs) in post-menopausal women. The study was terminated prematurely after an interim analysis showed an increased risk of breast cancer diagnosis, which led to a rapid decrease in MHT use worldwide. Subsequently, limitations of the study design and its interpretation in the context of other clinical studies has contributed to a more nuanced appreciation of the risk-benefit profile of differing MHT regimens regarding risk associated with the class of progestogen prescribed, its pattern of prescription, duration of use and timing of initiation related to menopause onset. This review provides a contextual interpretation of the WHI placebo-controlled study and evaluates the impact of bioidentical MHT, with a focus on combined therapies containing micronised progesterone, on the risk of chronic NCDs in post-menopausal women.

Interest & Impact

Downloads

1 since deposited on 22 May 2023
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item